Division of Pharmacy, Gunma Prefectural Cancer Center, Ota 373-8550, Gunma, Japan.
Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Gunma, Japan.
Medicina (Kaunas). 2021 Aug 4;57(8):801. doi: 10.3390/medicina57080801.
: Seasonal climatic changes may affect the development of the rash that is characteristic of treatment with anti-epidermal growth factor receptor (EGFR) antibodies. We evaluated the association between seasons and rash incidence among patients with cancer. : Data from patients with colorectal or head and neck cancer treated with cetuximab or panitumumab during summer (S group; = 34) or winter (W group; = 37) between June 2014 and February 2019 were collected to retrospectively examine patient characteristics and rash incidence ≤ 8 weeks after treatment initiation. Rashes were observed in 73.5% ( = 25) and 78.4% ( = 29) and grade 3 rashes were observed in 17.6% ( = 6) and 2.7% ( = 1) of the patients in the S and W groups, respectively. The incidence of grade ≥ 2 rashes in males in the S group was higher than that in the rest of the patient groups ( < 0.01). The higher incidence of skin rashes in males during summer might be attributed to the effects of ultraviolet light, lack of skincare, male hormones, and secretion of anti-EGFR antibodies in sweat. These findings highlight the need for research on preventive measures for such rashes.
季节气候变化可能会影响表皮生长因子受体（EGFR）抗体治疗相关皮疹的发生发展。我们评估了癌症患者皮疹发生与季节之间的相关性。
收集了 2014 年 6 月至 2019 年 2 月期间接受西妥昔单抗或帕尼单抗治疗的结直肠癌或头颈部肿瘤患者（S 组 n = 34 和 W 组 n = 37）夏季（S 组）和冬季（W 组）的数据，回顾性分析患者特征和治疗开始后≤8 周内皮疹的发生情况。S 组和 W 组分别有 73.5%（n = 25）和 78.4%（n = 29）的患者出现皮疹，分别有 17.6%（n = 6）和 2.7%（n = 1）的患者出现 3 级皮疹。S 组男性中≥2 级皮疹的发生率高于其他患者组（<0.01）。夏季男性皮肤皮疹发生率较高可能归因于紫外线的影响、缺乏皮肤护理、男性激素和汗液中抗 EGFR 抗体的分泌。这些发现强调了需要研究此类皮疹的预防措施。
